- ImmunityBio’s share price bearish trend continues since its merger despite Anktiva moving closer to a BLA submission in BCG-unresponsive non-muscle-invasive carcinoma in situ bladder cancer.
- This extensive sell-off is demoralizing and is inflicting max pain on longs. I believe the sell-off is being fueled by several sources, none of which are running empty.
- The company’s cytokine infusion protein and a novel interleukin-15 “IL-15” superagonist complex, Anktiva, could become a blockbuster product in the coming years.
- Regardless of the sell-off, I remain bullish on IBRX at these prices and will continue to follow my current strategy.
For further details see:
ImmunityBio: Demoralization Of The Bulls By Deflating The Share Price